Carcinoma Cervix
Carcinoma Cervix
CARCINOMA CERVIX
MAGNITUDE OF THE PROBLEM
NODES IN DIFFERENT
aConization (see p. 487)
TABLE 24.6: INVOLVEMENT OF LYMPH
STAGES (APPROXIMATE)
Paraaortic nodes (%) o Chest X-ray
Pelvic nodes (%) Pulmonary metastasis
Stage a Skeletal X-ray Bone metastasis
a Intravenous urogram/USG
la, (<3 mm) 0-0.5 Hydronephrosis
<1 O Barlum enema
la, (3-5 mm) 5 Large bowel involvement
2 n Proctoscopy
16 Rectal involvement
15
30 Ultrasonography, lymphangiography, CT and MRI, PET,
44
30 radlonucleotide scanning
optlonal and not to be studies, laparoscopy/laparotomy are
40 used for FIGO staging.
IV 55
282 Textbook of Gynecology
Tumor size ho than 4Cm is associated with more (ontd
Iymph node metastasis and joon suvival. Stage-IVB Spread to distant organs
Well diffeentiatet syuamous cell carcinonna grows lesions even
slowt and metastases late than the anaplastic type. " All macroscoplcally visible carcinomas. with superhcial
invasion are allotted to stage IB Invasion is
" Toung age is suallk associated with poorly differen to a measured stromal invasion with a
maximal o
depth limited
7.0 mm. Depth ofof50 mm
tiated squamous cell carinoma or
adenocarcinonma and a horizontal extension of not >
and is pnngnostically poor. should not be > 5.0 mm taken from the base of the eoithet irvaion
Iimph node imolvement (pevic and paraaortic) of the original tissue-superhcial or glandular. The da
of invasion should always be reported in mm, even in
rduces the sunival rate by 50%. cases with "early (minimal) stromal invasion" (~1.0 mm). Thethose
HPV ositie younger patients have better prognosis. involvement of vascular, lymphatic spaces should not change
lhe clinical staging as recommended by IGO is the stage allotment.
tabulatcd helow (2009) and shown in ligure 21.7. **On rectal examination, there is no cancer-free space behwese
the tumor and the pelvic wall. Alcases with hydronephrosis or
FIGO STAGING OF CARCINOMA OF THE CERVIX (2009)
non-functioning kidney are included, unless they are known to
be due to another cause.
Invasive Carcinona
Stage
Stage The carcinoma is strictly confined to the cervix SURGICAL STAGING OF CANCER CERVIX
(extension to the corpus would be disregarded)
Stage-iA Invasive carcinoma which can be diagnosed only There are often discrepancies between clinical staging
by microscopy with deepest invasion s S.0 mm and surgicopathological findings. Surgical staging can
and largest extension s 7.0 mm
minimize this by identifying the occult tumor spread and
Stage-iA1 Measured stromal invasion of s 3.0 mm in depth also the extrapelvic disease. Assessment of the pelvic
and horizontal extension of s 7.0 mm and paraaortic nodes are done by surgical approach.
Stage-IA2 Measured stromal invasion of > 3.0 mm and not > This is done either by extraperitoneal approach or by
5.0 mm with an extension of not > 7.0 mm laparoscopy.
Stage-IB Clinically visible lesions limited to the cervix uteri
DIAGNOSIS
or preclinical cancers greater than stage 1A*
Stage-1B1 Clinically visible lesion s 4.0 cm in greatest " Early carcinoma (Stage IA, IB, ILA)
dimension
Advanced carcinoma (Stage IB-IVB).
Stage-IB2 Clinically visible lesion > 4.0 cm in greatest
dimension Early Carcinoma
Cervical carcinoma invades beyond the uterus, but
Nomenclature: The concept of early carcinoma of the
Stage-1l
not to the pelvic wallor to the lower third of the cervix is not well-defined. Presumably, it should include
vagina those lesions which have got minimal morbidity and
Stage-IlA Without parametrial invasion
deaths with the best available therapy and a maximal
5-year survival rate (Table 24.8). With these criteria, the
Stage-1lA1 Clinically visible lesion s 4.0 cm in greatest following stages as per FIGO classification are includedin
dimension
the category of early carcinoma.
Stage-1A2 Clinically visible lesion > 4.0 cm in greatest Thus all these have got 5-year survival rates rangng
dimension
between 80-100%. Stage II reduces the 5-year survival
Stage-lIB With obvious parametrial invasion rate to as low as 55-70%. As such, it is inapproprlate to
Stage-ll The tumor extends to the pelvic wall and/or include any lesion extënding beyond Ithe cervix as early
involves lower third of the vagina and/or causes carcinoma:
hydronephrosis or nonfunctioning kidney* As the presentation of the case differs, these are
grouped as:
Stage-llA Tumor involves lower third of the vagina, with no " Preclinical " Clinical
extension to the pelvic wall
Stage-lB Extension to the pelvic wall and/or TABLE 24.8: EARLY CARCINOMA
hydronephrosis or nonfunctioning kidney
Stage S-year survival rate (%)
Stage-IV The carcinoma has extended beyond the true
pelvis or has involved (biopsy proven) the mucosa IA1 98.7
of the bladder or rectum. A bullous edema, as such, IA2 95.9
does not permit a case to be allotted to Stage IV IB1 90.4
Stage-IVA Spread of the growth to adjacent organs I82 79.8
Contd..
Chapter 24 Genital Malignancy 283
IA
IA1 IA2 IB1 (s 4 cm)
I82( 4 cm)
IIA1
IIA2
(s 4 cm)
(>4 cm)
-Lateral
parametrium
VUpper bwo-thirds
vagina Medial
parametrium
Lower-third vagina
IIIA IIB
Ureteric
obstruction
causing
hydroureter
and
hydronephrotic
Upper two-thirds changes
vagina
Lateral
Lower-third vagina pelvic wall
IVB
IVA
-Aortic nodes
Uterus
Bladder
-Rectum
Disadvantages of(below).
Surgery Women " Laparoscopic radical hysterectomy (LRH) with pelvic and
with comorbidities aortic lymphadenectomy is done for early invasive disease
See complications (stage I, ILA). The specimen is removed vaginally. Vaginal cuff
(obesity, heart disease) are at risk for surgery. is closed by endostitch. Pelvic and aortic lymphadenectomy
complications
Postoperative is done.
as observed following
Major postoperative complications have been discussed
otal abdominal hysterectomy
complications
Primary Radiotherapy
include: ureteric Cancer
(See p. 493). Other of the cervix was the first cancer of an internal
(about 1%), vesicovaginal fistula (0.5%), bladder
stula rectal dysfunction. organ to be treated with ionizing radiation using
ystunction, cystitis pyelonephritis andlymphedema of one radium by Margaret Cleves in 1903. Primary therapy
nere may be lymphocyst in the pelvis, mortality (chemoradiation) is given in locally advanced (stage IIB
dyspareunia, and recurrence. The to IVA)disease (see below).
von the legs,
Tate of the procedure is less than 1%. External photon beam radiation and
a known compli
Bladder dysfunction (atony) is sympathetic and are the two main methods (see p. 419, 420). brachytherapy
cation. This is due to damage from of the Both external beam radiation therapy (EBRT) and
and the bladder and
Parasympathetic fibers to drainage brachytherapy are delivered. External beam radiation
for bladder
urethra. Continuous catheterization usually preceeds intracavitary therapy
Smaintained for a periodof 6-10 days. (brachytherapy).
288 Textbook of Gynecology
TABLE 24.9: BRACHYTHERAPY TECHNIQUES Duration
No. of application
Amount of radium placement
Technique 120 hours
One
Paris Intrauterine tandem 33.3 mg-one
Vaginal ovoid 13.3 mg-two or three 72 hours each at
Intrauterine tandem 30-50 mg Two
Manchester interval of 7 days
Vaginal colpostat 30-50 mg
24 hours each at
Intrauterine tandem 50 mg-one Three
Stockholm weekly interval
Vaginal plaque-65-80 mg
treatment period in
weeks or afterloaded special applicators. One
EBRT is commonly given in 25 fractions during 5 Paris technique is 96-200 hours as compared
to Stockholm
in duration
(40-50 Gy).
radiation technique where each application is 24-28 hours
Hormone replacement therapy following
menopausal (Table 24.10). Manchester system, which is a modification of the
or surgery can be used for women with Paris technique, delivers constant isodose at different depths,
smptoms following counseling (see p. 50). regardless of the size of the uterus and vagina.
In Stockholm technique (Fig. 24.9), large high intensity
Advantages of Primary Radiotherapy source with less exposure time is given, but the vaginal source
is
Wider applicability in all stages of carcinoma cervix. closer to the cervix.
Survival rate 85%, comparable with that of surgery in
These three basic techniques are followed all through
early stages. the world in the brachytherapy for carcinoma cervix. After
Less primary mortality and morbidity.
Individualization of dose distributions/requirement loading remote control technique (see p. 419) is used
possible. for calculated dose distribution and to prevent radiaion
hazard. Fletcher-Suit afterloading modification systerm is
Early Stages widely used these days.
Brachytherapy technique (Table 24.9) is employed (see Ch 31).
Small radioactive sources, mainly radium sulfate is mixed with Disadvantages of Radiotherapy
some inert powder and packed in small needles or tubes. These Intestinal and urinary strictures, fistula formation (2-6%),
are used for interstitial, intracavitary or surface applications. vaginal fibrosis andstenosis causing dyspareunia, radiation
Radiation sources for intracavitary radiation are radium (26Ra), menopause (see p. 52), fibrosis ofbowel and bladder. Ovarian
cesium (137Cs) or Cobalt (G0Co). The container is made up of
platinum, gold or alloy steel to absorb alpha and beta particles transposition (ovariopexy) well out of the range of pelic
and allowing the gamma rays to sterilize the cancer cells. In irradiation may be done to avoid radiation menopanse. For
carcinoma cervix, the tandems are inserted in the uterine cavity other complications of radiation (see p. 421).
and the ovoids and colpostats are placed in the vaginal vault Calculation of the dose (see p. 420): The radium dose
under anesthesia. Different methods of brachytherapy are in is conventionally calculated with respect to the amount of
vogue (Fig. 24.9). High dose brachytherapy is safe and effective radiation received at two arbitrary points A and B. Point Ais
(NICE 2010). 2 cm cephalic and 2 cm lateral to the external os and is the point
In Paris and Manchester techniques, the source strength of crossing of the uterine artery and ureter. Point B is 2 cm
is smaller but exposure time is increased. The vaginal source cephalic and 5 cm lateral at the same plane and is approximately
is away from the cervix. They are used with either preloaded the site of obturator gland (see Fig. 31.3).
A B
Figs 24.9A to C: Different methods of brachytherapy-A. Stockholm technique: B. Paris technique: C. Manchester technique
Genital Malignancy
Chapter 24 "
nodes
calculated that point A gets about 7000 Surgery Followed by Radlotherapy with posltive lymph
. bus been cases
B 2000 cGy. Taking into consideration that This is indicatecl in
8000 Gy
and point
7000-7500 ciy, the rest of the detected following surgery.
invaslve carcinomacervix of
cancerohtic dose is approximatcly of
supplenmented by external beam irradiation Accidentaldiscovery hysterectomy.
nal point B is For external removed by simple present.
00) civ spreading over
another three weeks.
electron
a uterus
tlssue resection mnargin is sterilize the
energy of 4 million When positive therapy is to
iation, lincar accelerator with of this form of nodes. The fact remains
commonly used. The objective lymph possible
volts or mor is ofthe source, the vagína and cervix cancer cells in the pelvic dissection it is not reduced
ln the immediate vicinity node
Bladder, ureter, and pelvic lymph Radiation dose is
toerate about 20,000-30,000 cGy. otlher hand thateven by the positive nodes.
7000 cGy. Small gut on the
tum cantolerate up to 4500 cGy. to removeall 5 weeks.
fractions overchemoradiation therapy
of only 4500 cGy in 24
tolerance limit
Postoperative adjuvant platinum-based chemo
to
has a radiation damage to the adjacent
For the prevention of with gauze radiation and rate when
packing the vagina should be done carefully development (extended field improved the survival
iscera. or needles. Recent significantly
anound the vaginal ovoids applicator (colpostats) has
therapy)
radical hysterectomy.
inserts with plastic wall. given following
of rungsten irradiation of the vaginal
minimized excess gamma ofirradiation in rectum and
bladder is
RadiotherapyFollowed by Surgery
barrel-shaped cervix.
Calculation of the amount can be done carcinoma with growth
modification
required dose Endocervical controls sepsis, the
done by dosimeter and field-see p. 421). Radiotherapy
necessary (for treatment dosimetry, exact Bulkytumor: tumor resectability is improved.
as and when of computer shrinks and the
With the advent each patient for each chemotherapy (NACT) Reduces
of the doses on modulated " Neoadjuvant advantages: (a) disease
calculation ntensity following micrometastatic
provided. has the
application is being (IMRT), based on computer NACT volume (b) Reduces Probably
external radiation
therapy accurately the target tumor resectability and (d)
generated algorithmsnormal can distinguish Linear accelerators, (c) Improves in tumor compared to
radiotherapy
tissue. survival rate when with bulky
tissue volume and technology can deliver highly improves specially useful in young women Neoadjuvant
mulileaf collimation through IMRT. IMRT
can alone. It is for FSS.
precise external
radiotherapy
radiation to normal tissues stage IB-IIB disease desiring radioptherapy.
of chemotherapy is followed by
preferentially limit the dose doses to tumor tissues. It
can
platinum-based combination chemo
deliver higher Treatment Three cycles of weeks by
and can
are less amenable ordinarily. PET to radiation therapy followed 3-6
reat tumor that
imaging using CT, MR,
and therapy with
and lymphadenectomy is done. This
planningis done on 3D radical hysterectomy (stage
volume. of the bulky > 4 cm
determine the tumor blood supply is poo, the has improved the resectability regimen had shown better
cases: As the irradiating IIA) disease. This
J Advanced anoxia may be overcome bycondition of IB2 and bulky reduced recurrence.
resultant chamber under overall disease free survival rate and
special difficult. Risk of ureteric
hese cases in a Due to fibrosis, surgery may be
hyperbaric oxygenation. carcinoma: Incidence of used are in combination
about fistula may be more. The drugs
JRecurrent cervical
disease after therapy
is
beam of Cisplatin, Ifosfamide or Paclitaxel.
Tecurrence or persistent irradiation with
external Concurrent chemoradiation includes radiation
pelvic
35%. Whole
radiotherapy has been
advocated. hysterec and weekly cisplatin-based combination (cisplatin and
detected after simple upon the paclitaxel) chemotherapy. Cisplatin-based concurrent
Carcinoma, cervix depends
management protocol microinvasive/ chemoradiation is used as a treatment of choice in:
omy: The Cancer histology:
lollowing factors: (i) negative/positive; (a) Early stage (IA2, IB, IIA) disease after radical
tissuemargin: hysterectomy. (b) As a primary treatment for patients with
invasive;(ii)Surgical mass: absent o present.remove
(iii) Residual tumor Radical surgeryto This is bulky (24 cm) tumor (stage IB and IIA) and (c) Locally
options: (1) advanced (stage IMB to TVA) disease as a primary therapy.
Management
the regional nodes.
therapy:
Test of tissues including patient. (2) Radiation residual Chemotherapy sensitizes the cancer cells to radiation and
young minimal improves the survival rate.
specially done in a y there is no or residual
la) Brachytherapy whenradiotherapy when gross u Laparoscopic Assisted Vaginal Radical
disease. (b) Full intensity with Pelvic and Aortic Trachelectomy
disease is present. radiotherapy:
Perforation of the
ofuterine tandem.
Lymphadeectomy
was designed (Daniel Dargent 1987) to (LARVT)
Complications of
duringintroductlon complications
treat early
invasive cervical cancer. This is done in a young
erusmayresult major woman
are the where childbearing function is to be
Radiation reactions of surgery, (fertility sparing surgery). Initially, pelvic and preserved
(see p. 420). the form
is done. Vaginal aortic
In be done, one lymph node dissection
Combination herapy: chemotherapy imay
radiotherapy and trachelectomy is done only when these nodes radical
following the other. are
290 Textbook of Gynecology
PALLIATIVE TREATMENT
negative. laparnscopic appoAch is simlar to LARVH
to prde
(see p. 287). Vaginal part inchudes resection of cervical, Palliatlve treatment is primarly almed
along with
vaginal. paracervical, and paravaginal tissues. Vaginal comprehensive care for relief of symptoms
stage.
advanced
cuff is resected circumferentially about 2 cm below the treatment of cancer in the with
cenicovaginal junction. ldeally, the resected cervical discharge is treated
Apurulent or foul vaginal suppositories.
tissue margins should be free of disease as evaluated by antimicrobial vaginal creams or
frozen section. Cervical permanent cerclage operation
is done to prevent miscarriage and preterm labor. Bleeding or
Pallilative radlation therapy (180-200 eGy/day)
INDICATIONS OF TRACHELECTOMY of
chemotherapy may be used to relieve symptoms solutionpain or
Preservation of fertility bleeding. Tight vaginal pack soaked in Monsel's
(ferric subsulfate) against the cervix may control bleeding
Early stage disease (stage IA, A2, I81)
Small tumor volume (< 2 cm)
No pelvic node metastasis temporarily.
Cancer margin is at 1 cm below the internal os on MRI.
Pain
PLANNING OF TREATMENT MODALITIES
Palliation of pain is done either by reducing the pain
stimulus or by raising the pain threshold. Pain from bone
A. Early stage disease: See Table 24.10 metastasis is mainly due to prostaglandin production. It is
For early stage disease, the survival rate following best controlled by using nonsteroidal anti-inflarmmatory
treatment by either radical hysterectomy and pelvic drugs (NSAIDs). Palliative radiation with 2000 cGy over
Iynphadenectomy or with primary radiation with five treatment course mnay be an alternative. Anxiolytic
concurrent chemoradiation are almost equal. (benzodiazepines) or antidepressant drugs (amitriptyline)
B. Advanced stage disease may be helpful to raise the pain threshold. Opioid (oral